Nuclear receptors as pharmaceutical targets: Rise of FXR and rebirth of PPAR?

Future Medicinal Chemistry

Volumn 4, Issue 5, 2012, Pages 587-588

  Merk, Daniel ^a   Schubert Zsilavecz, Manfred ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

cdk5; fibrates; FXR; glitazars; metabolic disorders; PPAR; thiazolidindiones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CELL NUCLEUS RECEPTOR; FARNESOID X RECEPTOR; FIBRIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TESAGLITAZAR; TROGLITAZONE;

BLADDER CANCER; BONE DENSITY; CARDIOVASCULAR DISEASE; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DYSLIPIDEMIA; EDITORIAL; FLUID RETENTION; HUMAN; HYPERTRIGLYCERIDEMIA; LIVER TOXICITY; MUSCLE DISEASE; NONHUMAN; PRIORITY JOURNAL; RHABDOMYOLYSIS; SIDE EFFECT; WEIGHT GAIN;

HUMANS; LIGANDS; METABOLIC DISEASES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLIDINEDIONES;

EID: 84859466432     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.8     Document Type: Editorial

References (8)

1. Choi JH, Banks AS, Kamenecka AM et al. Antidiabetic actions of a non-agonist PPARg ligand blocking Cdk5-mediated phosphorylation. Nature 477, 477-483 (2011).
2. Wang N., Yin R, Liu Y, Mao G, Xi F. Role of peroxisome proliferator-activated receptor-g in atherosclerosis. Circ. J. 75, 528-535 (2011).
3. Renauld S, Tremblay K, Ait-Benichou S et al. Stimulation of ENaC activity by rosiglitazone is PPARc-dependent and correlates with SGK1 expression increase. J. Membrane Biol. 236, 259-270 (2010).
4. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Fibrate-associated adverse effects beyond muscle and liver toxicity. Curr. Pharm. Des. 14, 574-587 (2008).
5. Lindblom P, Berg AL, Zhang H et al. Tesaglitazar, a dual PPAR-a/g agonist. Hamster carcinogenicity, investigative animal and clinical studies. Toxicol. Pathol. 40, 18-32 (2011).
6. Ratner RE, Parikh S, Tou C. Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes. Diab. Vas. Dis. Res. 4, 214-221 (2007).
7. Fiorucci S, Mencarelli A, Distrutti E, Palladino G, Cipriani S. Targeting farnesoid-X-receptor: from medicinal chemistry to disease treatment. Curr. Med. Chem. 17, 139-159 (2010).
8. Lundquist J.T, Harnish DC, Kim CY et al. Improvement of physiochemical properties of the tetrahydroazepinoindole series of farnesoid X receptor (FXR) agonists: beneficial modulation of lipids in primates. J. Med. Chem. 53, 1774-1787 (2010).